Ask about this productRelated genes to: ASGR1 antibody
- Gene:
- ASGR1 NIH gene
- Name:
- asialoglycoprotein receptor 1
- Previous symbol:
- -
- Synonyms:
- CLEC4H1
- Chromosome:
- 17p13.1
- Locus Type:
- gene with protein product
- Date approved:
- 1988-05-24
- Date modifiied:
- 2016-10-05
Related products to: ASGR1 antibody
Related articles to: ASGR1 antibody
- - Source: PubMed
Ihsan UrwaAsif Ayesha - Tobacco smoking increases the risk of multiple diseases, but the biological mechanisms involved remain incompletely understood. Here we characterize smoking-related protein profiles to identify potentially causal biomarkers mediating smoking's effects. In European-ancestry populations, genetically predicted smoking exposures were significantly associated with levels of 93 (total: 2,922) proteins, including higher levels of asialoglycoprotein receptor 1 (ASGR1). The positive association of ASGR1 levels with ischemic heart disease (IHD) was supported by colocalization (posterior probability of hypothesis 4 = 0.91), and was estimated to explain 6.35% (95% confidence interval 2.61-10.09%, P = 8.77 × 10) of smoking's effects on IHD in two-step Mendelian randomization analyses. In network analyses, genetically predicted ASGR1 levels were inversely associated with plasma levels of more than 100 proteins, including growth arrest-specific 6, with all these proteins having rs55714927 (that is, a cis-protein quantitative trait locus for ASGR1) as a trans-protein quantitative trait locus. Sensitivity analyses in never-smokers identified a nonstatistically significant residual association between ASGR1 and IHD, which is consistent with possible horizontal pleiotropy, with body mass index implicated as a potential contributing pathway. - Source: PubMed
Publication date: 2026/09/22
Tinworth Alexander CYao PangIona AndriPozarickij AlfredVon Ende AdamMillwood Iona YWalters Robin GClarke RobertBragg FionaChen Zhengming - Asialoglycoprotein receptor 1 (ASGR1), a hepatocyte-specific receptor, represents a potential therapeutic target for hypercholesterolemia. However, liver safety risks of ASGR1-targeted therapies remain poorly characterized. This study aims to investigate the impact of ASGR1 deficency on liver fibrosis and its underlying mechanisms. - Source: PubMed
Zhu HuiHuang Xin-PingYou KaiChen YanLi Peng-HuiTao Jia-WangYu Xiao-RuiXu Jie-HuiXu Guo-ShengLi Yin-Xiong - Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease with limited therapeutic options. Hepatocyte senescence is a critical driver of MASLD progression, but its upstream regulators remain poorly understood. This study aims to investigate the role and mechanism of high expression of asialoglycoprotein receptor 1 (ASGR1) in MASLD-associated hepatocyte senescence. - Source: PubMed
Publication date: 2026/08/19
Zhang Chen-YuDing JieSun Yi-JiaZhong Wen-JingYang Nan-Si-YuLi Pei-ZeZheng Jia-HuiYang Jin-TongLiang Li-YingZhou YongTang Si-YuanHuang Xiao-Ting - Barker's hypothesis posits that adverse in utero exposures, often reflected by low birthweight, increase adult cardiovascular disease (CVD) risk. However, underlying mechanisms remain unclear; identifying potentially causal mediators is crucial for developing effective interventions. Emerging research suggests epigenetic modifications may influence CVD traits from early life. We aimed to identify DNA methylation (DNAm) signatures that mediate birthweight and CVD traits and to establish their biological relevance across three developmental time points using multi-omics integration. - Source: PubMed
Publication date: 2026/08/14
Tang John YenNg Nicole Ying TingKwok Alice Wing SzeMak Christopher Chun YuCheung Yiu-FaiChung Brian Hon Yin